Datavault AI (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The expanded relationship is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
This expansion signals a significant shift in how healthcare data could be managed and monetized. By integrating Datavault AI’s Web 3.0 and artificial intelligence capabilities, the partnership aims to give patients greater control over their health information, allowing them to consent to data sharing and potentially earn compensation. The move also positions Datavault AI to tap into the growing health and wellness market, which includes personalized medicine, remote monitoring, and wearable devices.
The full press release is available at https://ibn.fm/vBAxH. Datavault AI’s technology suite includes acoustic sciences and data sciences divisions, with patented technologies in wireless high-definition sound and data valuation. The company serves multiple industries, including healthcare, biotech, and fintech, through its Information Data Exchange platform that enables digital twins and secure metadata attachment.
The implications of this agreement are far-reaching. For patients, it could mean more autonomy over personal health data and potential financial benefits. For healthcare providers and researchers, it could facilitate access to richer datasets while ensuring compliance with privacy regulations. For investors, the deal highlights Datavault AI’s strategic pivot towards high-growth sectors like health and wellness. However, the company noted in its forward-looking statements that actual results may differ due to risks outlined in its SEC filings.
